Why Peptides

01 — What peptides are

A peptide is a short chain of amino acids. Proteins are long chains — insulin, for example, is a 51-amino-acid peptide that sits right at the fuzzy boundary between the two. Shorter peptides are often called “signaling molecules” because that’s essentially what they do in the body: bind to receptors and tell cells to start, stop, or change a specific behavior.

Your body makes peptides naturally. Growth hormone releasing hormone (GHRH), thymosin, oxytocin, glucagon — these are all peptides your own cells produce every day. Therapeutic peptides are either synthetic copies of these natural signals, deliberately modified versions designed to last longer or bind more selectively, or entirely novel sequences identified through research.

The shorter way to say it: peptides are small, targeted biological instructions. Medicine’s ability to synthesize and prescribe them has improved substantially in the last two decades. That’s why you’re hearing about them now.

02 — How peptides work in the body

Most peptides work through receptor binding. A peptide fits a specific receptor on a cell surface, the receptor triggers an internal signaling cascade, and the cell responds — by releasing a hormone, dividing, repairing damage, migrating to a site of injury, or any of dozens of other actions.

Because peptides are signal molecules rather than broad biochemical hammers, their effects tend to be more specific than small-molecule drugs. Semaglutide doesn’t “cause weight loss” in a general sense; it activates GLP-1 receptors, which slow gastric emptying and modulate appetite signaling in the hypothalamus.

This specificity is both the category’s strength and its limitation. Peptides can target mechanisms small molecules can’t touch. But they also tend to have narrower windows of benefit, meaning dose, timing, and monitoring matter more than with most prescriptions.

03 — The regulatory landscape

This is where most patients get lost, and where most clinics — deliberately or not — blur the line. There are three distinct regulatory categories a peptide can fall into:

FDA-approved peptide medications

Certain brand-name peptide products — for example, Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide), Vyleesi (bremelanotide), and Forteo (teriparatide) — have completed clinical trials and received FDA approval for specific indications. These are commercial pharmaceuticals. Compounded versions of these ingredients are not FDA-approved. They can be prescribed when clinically indicated and where permitted under current FDA rules.

Peptides without FDA approval

Many peptides — BPC-157, TB-500, sermorelin, and others — are not available as commercial pharmaceuticals in the U.S. They are not FDA-approved. Their regulatory status varies by peptide and the rules have shifted in recent years; we discuss the current status of any peptide with you during your consultation.

Research-only peptides

A large category of peptides have only been studied in animals or in very limited human trials. These are sold by “research chemical” vendors online, typically labeled “not for human use.” We do not prescribe these. Neither should anyone else who calls themselves a clinic.

When evaluating a peptide clinic, the single most useful question is: “Which regulatory category is this peptide in, and how do you know?” The answer — or the lack of one — tells you almost everything.

04 — Safety and side effects

No peptide is “free of risk,” and for peptides without FDA approval, human safety has not been established. Side effects vary widely by peptide. GLP-1 agonists commonly cause GI symptoms, especially during dose titration. Growth hormone secretagogues can cause water retention, joint discomfort, and blood sugar changes. PT-141 can cause flushing, nausea, and blood pressure fluctuations.

The more important safety considerations are often structural:

• Source and sterility — underground peptides carry real infection risk.
• Drug interactions, especially with cardiovascular, endocrine, or psychiatric medications.
• Long-term data — for newer peptides, we simply don’t have decades of outcome data yet.
• Appropriate monitoring — follow-up visits and repeat labs where clinically indicated.

Our clinical philosophy is conservative on dose, strict on sourcing, and transparent about uncertainty. If we don’t know something, we tell you.

05 — What peptides are not

Peptides are not steroids. Anabolic steroids are modified testosterone molecules, a completely different class with a different mechanism.

Peptides are not supplements. Supplements are regulated as food; they don’t require prescription, physician oversight, or regulated manufacturing. Most peptides, when used therapeutically, do.

Peptides are not a miracle category. Marketing implies otherwise. Clinical evidence, appropriately weighted, does not. Some peptides have strong evidence for specific outcomes. Some have promising but limited data. Some have almost no human data. A good clinic will tell you which is which.

06 — Myth vs. evidence

A few of the most common misconceptions we encounter:

“BPC-157 heals anything.”

BPC-157 has been studied mainly in animal models. Benefit in people has not been established, it is not FDA-approved, and The Tide does not offer it.

“Growth hormone peptides turn back aging.”

GH-releasing peptides can raise IGF-1 levels, but clinical benefit in healthy adults has not been established. They do not reverse aging in any meaningful clinical sense. Anyone selling them that way is selling you a story.

“Research peptides from online vendors are the same thing.”

They are not. Research-grade product has no manufacturing oversight, no sterility guarantee, no dose verification, and no legal pathway for therapeutic use. We will not prescribe alongside them and strongly discourage their use.

Ready to go deeper? Continue to the Peptide Library or explore by clinical goal.